https://smallcaps.com.au/wattle-health-australia-infant-formula-m...

https://smallcaps.com.au/wattle-health-australia-infant-formula-mainland-china/

The deal meant that Wattle’s conventional cow infant formula would be made available for sale in traditional retail centres in mainland China and ensured that the company reached an important milestone which boosted its growing footprint in the country.

The total size of that particular deal was substantially larger compared to the one announced today with Shandong – Wattle said it anticipated revenues to exceed A$100 million across a three-year period and confirmed that the deal is backed by a bank guarantee.